Circadin

DRUG5 trials

Sponsors

Neurim Pharmaceuticals Ltd., Seoul National University Hospital

Conditions

Alzheimer's DiseaseDiabetes Mellitus, Type 2InsomniaPrimary InsomniaREM Sleep Behavior DisorderSleep Disorder

Phase 2

Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs

CompletedNCT00816673

Neurim Pharmaceuticals Ltd.Primary Insomnia

Start: 1996-09-30End: 1997-09-30Updated: 2024-11-14

A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

CompletedNCT00869128

Neurim Pharmaceuticals Ltd.Diabetes Mellitus, Type 2, Insomnia

Start: 1995-11-30End: 1997-03-31Updated: 2009-05-01

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

CompletedNCT00940589

Neurim Pharmaceuticals Ltd.Alzheimer's Disease, Sleep Disorder

Start: 2009-09-30End: 2013-05-31Updated: 2018-06-01

Phase 3

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

CompletedNCT00397189

Neurim Pharmaceuticals Ltd.Primary Insomnia

Start: 2006-10-31End: 2009-04-30Updated: 2018-05-01

Phase 4

Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study

Seoul National University HospitalREM Sleep Behavior Disorder

Start: 2016-01-31End: 2017-12-31Target: 30Updated: 2017-04-28

Related Papers

Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response.

2010-11-2469 citations